Publication

Effect of magnesium treatment and glucose levels on delayed cerebral ischemia in patients with subarachnoid hemorrhage: a substudy of the Magnesium in Aneurysmal Subarachnoid Haemorrhage trial (MASH-II)

Leijenaar, J. F., Mees, S. M. D., Algra, A., van den Bergh, W. M., Rinkel, G. J. E. & MASH-II Study Grp, Oct-2015, In : International Journal of Stroke. 10, p. 108-112 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Effect of magnesium treatment and glucose levels on delayed cerebral

    Final publisher's version, 141 KB, PDF document

    Request copy

DOI

BackgroundMagnesium treatment did not improve outcome in patients with aneurysmal subarachnoid haemorrhage in the Magnesium in Aneurysmal Subarachnoid Haemorrhage II trial. We hypothesized that high glucose levels may have offset a potential beneficial effect to prevent delayed cerebral ischemia. We investigated if magnesium treatment led to less delayed cerebral ischemia and if glucose levels interacted with magnesium treatment in the Magnesium in Aneurysmal Subarachnoid Haemorrhage II trial.

AimTo investigate the effect of magnesium treatment on occurrence of delayed cerebral ischemia and the interaction between glucose levels and magnesium treatment in subarachnoid hemorrhage patients.

MethodsThe Magnesium in Aneurysmal Subarachnoid Haemorrhage was a phase III randomized placebo-controlled trial assessing the effect of magnesium sulphate on clinical outcome in aneurysmal subarachnoid hemorrhage patients. For the current study, we included only the patients admitted to the University Medical Centre-Utrecht. We calculated hazard ratios for occurrence of delayed cerebral ischemia in patients treated with magnesium vs. placebo for the entire study population, and separately in the subgroups of patients with high and low mean fasting and mean daily glucose levels until onset of delayed cerebral ischemia. We used the cross-product of magnesium and glucose in the regression analysis to evaluate whether an interaction between magnesium and glucose existed.

ResultsWe included 616 patients: 307 received magnesium and 309 placebo; 156 patients had delayed cerebral ischemia. Hazard ratio for magnesium on occurrence of delayed cerebral ischemia was 10 (95% confidence interval: 07-14). Results were similar in patients with low or high fasting or daily glucose levels. We found no interactions between magnesium treatment and high fasting (P=054) and daily glucose (P=060).

ConclusionsMagnesium treatment did not reduce the risk of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage, nor was there an interaction with glucose levels. It is therefore unlikely that glucose levels explain the failure of magnesium to prevent delayed cerebral ischemia and poor outcome after aneurysmal subarachnoid hemorrhage.

Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalInternational Journal of Stroke
Volume10
Publication statusPublished - Oct-2015

    Keywords

  • DCI, delayed cerebral ischemia, glucose, magnesium, SAH, subarachnoid hemorrhage, MILD HYPOTHERMIA 35-DEGREES-C, RANDOMIZED CONTROLLED-TRIAL, STROKE TRIAL, EFFICACY, RAT

ID: 28337157